This article was originally published on PharmaTimes http://www.pharmatimes.com/news/interim_data_shows_stelara_promise_in_chrons_1325725

Interim data from the Phase IIIb STARDUST study showed that 79% of patients with moderately to severely active Crohn’s disease (CD) achieved clinical response and 67% were in clinical remission.

Related Posts